Dengue Virus Serotype 2 VLP Mouse anti Dengue virus serotype 2 NS1 monoclonal antibody Dengue virus serotype 4 VLP Mouse anti Dengue virus serotype 1+4 NS1 monoclonal antibody

Dengue Virus Serotype 1 VLP

Product TypeMammalian recombinant
Purity>95% pure by SDS-PAGE
StrainPuerto Rico/US/BID-V853/1998
PresentationLiquid
Protein Conc.0.1-0.8 mg/ml
Product CodeDENV1-VLP
Vial Size100μg | 250μg | 500μg

From: $837.00

Clear
SKU: DENV1-VLP Category:

Product Description

Dengue Virus Serotype 1 VLP

Dengue Virus Serotype 1 VLP (Virus-Like Particle) is a new, unique product that has been developed in response to the need for highly immunogenic, concentrated Dengue antigens for use in Dengue focussed disease research and vaccine development (including use as an immunogen). Like its related product, Dengue Virus Serotype 1 NS1, the Dengue Virus Serotype 1 VLP is produced in human cell lines using state-of-the-art expression techniques. The Native Antigen Company Dengue Virus Serotype 1 VLP is constructed from E, M and preM proteins, with secretion from the cell aided by substituting the C terminal 20% with the corresponding Japanese Encephalitis Virus sequence (all internal/transmembrane). Concentration and purification is then performed by a series of ultracentrifuge and chromatographical methods which result in VLPs of exceptional quality and purity (See the DENV2-VLP QC analysis). Cleavage of preM protein occurs naturally by furin in the cell and results in a dual population of preM and M-containing VLPs.

Virus-Like Particles (VLPs) are an emerging vaccine technology. VLPs consist of  protein shells comprising outer proteins specific to the virus in question. VLPs are more representative of how viral antigens are presented in vivo and while they are highly immunogenic they are non-infectious as they lack the core genetic material of the virus. Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide effective protection and are in current use for several diseases and in development for many others.

With more than one-third of the world’s population living in areas at risk of transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics (ref WHO for Guidelines for Diagnosis, Treatment, Prevention & Control, 2009) As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are no vaccines available to prevent infection with dengue virus.

Dengue virus Serotype 2, Serotype 3 and Serotype 4 VLPs are also now available.

Additional Information

Vial Size

100μg, 250μg, 500μg

SDS DENV VLP  SDS DENV VLP

CofA DENV1-VLP-250 Batch 15062616  CofA DENV1-VLP-250 Batch 15062616

Menu